Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder

Trial Profile

Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Guanfacine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Shionogi; Shire
  • Most Recent Events

    • 20 Sep 2017 Shionogi will evaluate the full data and will investigate plans for disclosure of detailed data, as reported in a Shionogi media release.
    • 20 Sep 2017 Results published in the Shionogi Media Release
    • 20 Sep 2017 Primary endpoint has been met. (Change in the baseline of the ADHD evaluation scale in the INTUNIV group), as reported in a Shionogi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top